ISCT Cell Therapy Commercial Development Series
Industry access to information through connection with key opinion leaders (KOLs) in global regulatory, reimbursement and translational medicine space has great value. The ISCT Cell Therapy Commercial Development series allows Industry Community members access to discussion forums to contribute to the development of cell therapy commercialization pathways and to gain front row insight on issues that influence the and drive key development decisions.
The ISCT Cell Therapy Commercial Development series has 2 streams of events:
• Clinical Development Focus Groups
• BMCOGS and Reimbursement Roundtables
The topics for both streams are driven by the ISCT Industry Community member commercial development priorities.
To foster direct and focused exchange on development challenges, a small town-hall forum has been developed for the series with a cap on attendance of 30. The composition of attendees will be driven by the topic but will comprise industry, academic, clinical, regulatory, investment stakeholders. Priority for industry seats will be given to ISCT Industry Community members.
Participant Benefits:
• Pre-event introductory education when necessary.
• 4 hour in person roundtable perspective sharing and moderated discussion of key issues with international renowned KOLs.
• Opportunity to network with KOLs
• Participant only access to a detailed report of the roundtable discussions and recommendations.
ISCT Commercial Development Series Outcomes:
It is ISCT’s intent that the international field of cell therapy and regenerative medicine will be able to benefit from the series through public open access to the final report and outcomes. A summary report with outcomes, recommendations and/or actionable next steps will be developed for each event and distributed publically as is content appropriate.
Reports will be 2-tiered :
• A detailed report of the roundtable discussions and recommendations will be made available to all participants.
• A summary report with outcomes, recommendations and/or actionable next steps will be distributed publically as is content appropriate.
When relevant the roundtable summary report will be submitted for publication to Cytotherapy – the official journal of ISCT, or partner publications with first priority to ISCT publications.
Early access to the roundtable report is offered as a benefit to all participants and to ISCT Commercialization Committee and ISCT Industry Community members
